On May 27, 2022, Fudan-Zhangjiang is★¶ sued an announcement $☆∑÷stating that the compan‍÷φ←y intends to cooperate with WD Pharma o→ ♣n WD-1603 and sign related agree'≤σΩments. The subject of this c♥ ooperation is a prodλ£&uct for the treatment ​↕≠♣of Parkinson's disease being de&¶veloped by WD Pharma, which is ↕ a product using a proprieta​​ry technology, with controlled-releas§'e components for the treatment of ♠✔Parkinson's disease, which is cur •±rently at Phase II clinical tφ×rials. The Company wil☆γl conduct Phase III clinical trials bas∞'£ ed on the completion of Phase II cφ→☆δlinical trials and th¥Ω'™e achievement of exp←' ♠ected results by WD Pharma. The Comp©<Ωγany will become the Mark€≤eting Authorization Holder (MAH) for ←&the product in Mainland Chi ®na and will be respo$₽¥∑nsible for manufacturing